NEW YORK, NY / ACCESSWIRE / May 31, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Intersect ENT, Inc. ("Intersect" or the "Company")(XENT) of the July 15, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested inIntersect stock or options between August 1, 2019 and May 6, 2019 and would like to discuss your legal rights, clickhere: www.faruqilaw.com/XENT. Thereis no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all those who purchased Intersect securities between August 1, 2019 and May 6, 2019 (the "Class Period"). The case, Yaron v.Intersect ENT, Inc. et al., No. 19-cv-02647 was filed on May 15, 2019, and has been assigned to Judge Lucy H. Koh.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company lacked adequate reimbursement representatives to ensure physicians had access to SINUVA; (2) that, as a result, the Company's sales force would focus on ensuring reimbursement; (3) that, as a result, the Company's sales representatives were less focused on driving sales; (4) that physicians were less likely to adopt the Company's SINUVA due to transaction costs associated with seeking reimbursement; (5) that the Company would increase staffing to address these issues; and (6) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 1, 2018, before the market opened, the Company disclosed that it faced certain challenges with the launch of SINUVA, which had negatively impacted the Company's second quarter 2018 financial results.

On this news, Intersect's share price fell from $32.35 per share on July 31,2018 to a closing price of $26.05 on August 1, 2018: a $6.30 or a 19.4% drop.